<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25404952</article-id><article-id pub-id-type="pmc">4233234</article-id><article-id pub-id-type="publisher-id">75</article-id><article-id pub-id-type="doi">10.1186/s13195-014-0075-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>β-site amyloid precursor protein-cleaving
enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid
precursor protein cleavage</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Portelius</surname><given-names>Erik</given-names></name><address><email>erik.portelius@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Dean</surname><given-names>Robert A</given-names></name><address><email>DEAN_ROBERT_A@LILLY.COM</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Andreasson</surname><given-names>Ulf</given-names></name><address><email>ulf.andreasson@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Mattsson</surname><given-names>Niklas</given-names></name><address><email>niklas.mattsson@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff1"></xref><xref ref-type="aff" rid="Aff3"></xref></contrib><contrib contrib-type="author"><name><surname>Westerlund</surname><given-names>Anni</given-names></name><address><email>anni.westerlund@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Olsson</surname><given-names>Maria</given-names></name><address><email>maria.olsson@clinchem.gu.se</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Demattos</surname><given-names>Ronald Bradley</given-names></name><address><email>demattos_ronald_bradley@lilly.com</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Racke</surname><given-names>Margaret M</given-names></name><address><email>racke_margaret@lilly.com</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Zetterberg</surname><given-names>Henrik</given-names></name><address><email>Henrik.zetterberg@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff1"></xref><xref ref-type="aff" rid="Aff4"></xref></contrib><contrib contrib-type="author"><name><surname>May</surname><given-names>Patrick C</given-names></name><address><email>may_patrick_c@lilly.com</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Blennow</surname><given-names>Kaj</given-names></name><address><email>kaj.blennow@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><aff id="Aff1"><label></label>Clinical Neurochemistry Laboratory, Institute of Neuroscience and
Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, S-431 80 Mölndal, Sweden </aff><aff id="Aff2"><label></label>Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 USA </aff><aff id="Aff3"><label></label>San Francisco VA Medical Center, Center for Imaging of
Neurodegenerative Diseases (CIND), University of California San Francisco, San Francisco, CA USA </aff><aff id="Aff4"><label></label>UCL Institute of Neurology, Queen Square, London, WC1N 3BG UK </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>6</volume><issue>9-9</issue><elocation-id>75</elocation-id><history><date date-type="received"><day>6</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>14</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>© Portelius et al.; licensee BioMed Central
Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons
Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless
otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="5597" xml_f="5609" txt_i="11" txt_f="23">Introduction</offsets></title><p><offsets xml_i="5620" xml_f="6203" txt_i="24" txt_f="607">The β-secretase enzyme, β-site amyloid precursor protein-cleaving
enzyme 1 (BACE1), cleaves amyloid precursor protein (APP) in the first step in
β-amyloid (Aβ) peptide production. Thus, BACE1 is a key target for candidate
disease-modifying treatment of Alzheimer’s disease. In a previous exploratory Aβ
biomarker study, we found that BACE1 inhibitor treatment resulted in decreased
levels of Aβ1-34 together with increased Aβ5-40, suggesting that these Aβ species
may be novel pharmacodynamic biomarkers in clinical trials. We have now examined
whether the same holds true in humans.</offsets></p></sec><sec><title><offsets xml_i="6225" xml_f="6232" txt_i="609" txt_f="616">Methods</offsets></title><p><offsets xml_i="6243" xml_f="6328" txt_i="617" txt_f="702">In an investigator-blind, placebo-controlled and randomized study,
healthy subjects (</offsets><italic><offsets xml_i="6336" xml_f="6337" txt_i="702" txt_f="703">n</offsets></italic><offsets xml_i="6346" xml_f="6423" txt_i="703" txt_f="780"> =18) were randomly assigned
to receive a single dose of 30 mg of LY2811376 (</offsets><italic><offsets xml_i="6431" xml_f="6432" txt_i="780" txt_f="781">n</offsets></italic><offsets xml_i="6441" xml_f="6467" txt_i="781" txt_f="807"> =6), 90 mg of LY2811376 (</offsets><italic><offsets xml_i="6475" xml_f="6476" txt_i="807" txt_f="808">n</offsets></italic><offsets xml_i="6485" xml_f="6503" txt_i="808" txt_f="826"> =6),
or placebo (</offsets><italic><offsets xml_i="6511" xml_f="6512" txt_i="826" txt_f="827">n</offsets></italic><offsets xml_i="6521" xml_f="6658" txt_i="827" txt_f="964"> =6). We used hybrid
immunoaffinity-mass spectrometry (HI-MS) and enzyme-linked immunosorbent assays to
monitor a variety of Aβ peptides.</offsets></p></sec><sec><title><offsets xml_i="6680" xml_f="6687" txt_i="966" txt_f="973">Results</offsets></title><p><offsets xml_i="6698" xml_f="6974" txt_i="974" txt_f="1250">Here, we demonstrate dose-dependent changes in cerebrospinal fluid
(CSF) Aβ1-34, Aβ5-40 and Aβ5-X after treatment with the BACE1-inhibitor LY2811376.
Aβ5-40 and Aβ5-X increased dose-dependently, as reflected by two independent
methods, while Aβ1-34 dose-dependently decreased.</offsets></p></sec><sec><title><offsets xml_i="6996" xml_f="7006" txt_i="1252" txt_f="1262">Conclusion</offsets></title><p><offsets xml_i="7017" xml_f="7566" txt_i="1263" txt_f="1812">Using HI-MS for the first time in a study where subjects have been
treated with a BACE inhibitor, we confirm that CSF Aβ1-34 may be useful in
clinical trials on BACE1 inhibitors to monitor target engagement. Since it is less
hydrophobic than longer Aβ species, it is less susceptible to preanalytical
confounding factors and may thus be a more stable marker. By independent
measurement techniques, we also show that BACE1 inhibition in humans is associated
with APP-processing into N-terminally truncated Aβ peptides via a
BACE1-independent pathway.</offsets></p></sec><sec><title><offsets xml_i="7588" xml_f="7606" txt_i="1814" txt_f="1832">Trial registration</offsets></title><p><offsets xml_i="7617" xml_f="7636" txt_i="1833" txt_f="1852">ClinicalTrials.gov </offsets><ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT00838084"><offsets xml_i="7722" xml_f="7733" txt_i="1852" txt_f="1863">NCT00838084</offsets></ext-link><offsets xml_i="7744" xml_f="7846" txt_i="1863" txt_f="1965">. Registered: First received: January 23, 2009, Last updated: July
14, 2009, Last verified: July 2009.</offsets></p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title><offsets xml_i="8101" xml_f="8113" txt_i="1974" txt_f="1986">Introduction</offsets></title><p><offsets xml_i="8124" xml_f="8353" txt_i="1987" txt_f="2216">Alzheimer’s disease (AD) is a slowly progressing brain disease
manifesting several neuropathological characteristics including accumulation of
extracellular plaques, mainly composed of amyloid-β (Aβ) peptides of various lengths
[</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="8385" xml_f="8386" txt_i="2216" txt_f="2217">1</offsets></xref><offsets xml_i="8393" xml_f="8394" txt_i="2217" txt_f="2218">,</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="8426" xml_f="8427" txt_i="2218" txt_f="2219">2</offsets></xref><offsets xml_i="8434" xml_f="8604" txt_i="2219" txt_f="2389">]. Aβ is derived via two-step enzymatic cleavage of the
transmembrane amyloid precursor protein (APP) catalyzed by the β-site APP-cleaving
enzyme 1 (BACE1, β-secretase) [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="8636" xml_f="8637" txt_i="2389" txt_f="2390">3</offsets></xref><offsets xml_i="8644" xml_f="8663" txt_i="2390" txt_f="2409">] and
γ-secretase [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="8695" xml_f="8696" txt_i="2409" txt_f="2410">4</offsets></xref><offsets xml_i="8703" xml_f="8986" txt_i="2410" txt_f="2693">]. BACE1 cleaves APP at
the first amino acid of the Aβ domain and is crucial for the production of Aβ
peptides starting at position 1, including Aβ1-42. Thus, BACE1 is a key target for
disease-modifying AD treatments, since one focus for such therapies is to minimize
Aβ production [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="9018" xml_f="9019" txt_i="2693" txt_f="2694">5</offsets></xref><offsets xml_i="9026" xml_f="9028" txt_i="2694" txt_f="2696">].</offsets></p><p><offsets xml_i="9035" xml_f="9162" txt_i="2697" txt_f="2824">To evaluate the biochemical effects of novel BACE1 inhibitor
candidates, biomarkers that reflect target engagement are needed [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="9194" xml_f="9195" txt_i="2824" txt_f="2825">6</offsets></xref><offsets xml_i="9202" xml_f="9325" txt_i="2825" txt_f="2948">]. Analyzing a wide range of Aβ species in
cerebrospinal fluid (CSF) gives useful information on APP metabolism in humans
[</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="9357" xml_f="9358" txt_i="2948" txt_f="2949">7</offsets></xref><offsets xml_i="9365" xml_f="9366" txt_i="2949" txt_f="2950">,</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="9398" xml_f="9399" txt_i="2950" txt_f="2951">8</offsets></xref><offsets xml_i="9406" xml_f="9761" txt_i="2951" txt_f="3306">]. In a recent preclinical study, we showed that APP-transfected
cells and dogs treated with several different BACE1-inhibitors expressed decreased
levels of Aβ1-34 and concurrently increased the levels of Aβ5-40 in cell media and
CSF, suggesting that these peptides may be pharmacodynamic markers of BACE1
inhibition in the central nervous system (CNS) [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="9793" xml_f="9794" txt_i="3306" txt_f="3307">9</offsets></xref><offsets xml_i="9801" xml_f="9930" txt_i="3307" txt_f="3436">]. Inhibition of γ-secretase, another AD drug candidate approach,
increased APP processing via the α-secretase-mediated pathway [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="9963" xml_f="9965" txt_i="3436" txt_f="3438">10</offsets></xref><offsets xml_i="9972" xml_f="9973" txt_i="3438" txt_f="3439">-</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="10006" xml_f="10008" txt_i="3439" txt_f="3441">13</offsets></xref><offsets xml_i="10015" xml_f="10204" txt_i="3441" txt_f="3630">] and decreased CSF levels of Aβ1-34 in humans, even at dosages
when Aβ1-42 was unchanged, further supporting the use of novel CSF biomarkers to
monitor target engagement of anti-Aβ drugs [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="10237" xml_f="10239" txt_i="3630" txt_f="3632">14</offsets></xref><offsets xml_i="10246" xml_f="10247" txt_i="3632" txt_f="3633">-</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="10280" xml_f="10282" txt_i="3633" txt_f="3635">16</offsets></xref><offsets xml_i="10289" xml_f="10291" txt_i="3635" txt_f="3637">].</offsets></p><p><offsets xml_i="10298" xml_f="10841" txt_i="3638" txt_f="4181">Here, for the first time with a peptidomics approach, we have
demonstrated changes in CSF levels of Aβ1-34 and Aβ5-40 in humans treated with the
BACE1 inihibitor LY2811376 (Eli Lilly and Company, Indianapolis, IN, USA). The
translation of these findings from preclinical models to man indicates that CSF
Aβ1-34 and Aβ5-40 have potential utility as markers of BACE1 inhibition in clinical
research. Furthermore, the results strongly suggest that Aβ peptides starting at
amino acid 5 are produced through a non BACE1-dependent pathway in humans.</offsets></p></sec><sec id="Sec2" sec-type="materials|methods"><title><offsets xml_i="10902" xml_f="10909" txt_i="4183" txt_f="4190">Methods</offsets></title><sec id="Sec3"><title><offsets xml_i="10939" xml_f="10947" txt_i="4191" txt_f="4199">Subjects</offsets></title><p><offsets xml_i="10958" xml_f="11101" txt_i="4200" txt_f="4343">The study, conducted at PAREXEL International Early Phase Los
Angeles, CA, USA, from February to June 2009, was previously reported in detail
[</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="11134" xml_f="11136" txt_i="4343" txt_f="4345">17</offsets></xref><offsets xml_i="11143" xml_f="12212" txt_i="4345" txt_f="5414">]. In brief, the study was a
subject- and investigator-blind, placebo-controlled, randomized, single-dose
design. The California Institutional Review Board approved the study. All subjects
provided written informed consent before the beginning of the study. The trial was
conducted in compliance with the Declaration of Helsinki and International
Conference on Harmonisation/Good Clinical Practice guidelines. Eighteen healthy
subjects (21 to 49 years old, seventeen men and one woman) participated in the
study and were randomly assigned to receive a single dose of 30 mg of LY2811376 (n
=6), 90 mg of LY2811376 (n =6) or placebo (n =6). An indwelling lumbar catheter
was placed four hours before administration of the study drug and subjects
remained supine for the duration of the CSF sample collection period. CSF samples
were collected prior to and at regular intervals over 36 hours after drug
administration and analyzed by immunoprecipitation in combination with mass
spectrometry (MS). All CSF samples were collected in polypropylene tubes and
stored at -80°C.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="12244" xml_f="12283" txt_i="5416" txt_f="5455">Hybrid immunoaffinity-mass spectrometry</offsets></title><p><offsets xml_i="12294" xml_f="12517" txt_i="5456" txt_f="5679">Immunoaffinity capture of Aβ species was combined with
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS for
analyzing a variety of Aβ peptides in a single analysis as described in detail
elsewhere [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="12550" xml_f="12552" txt_i="5679" txt_f="5681">18</offsets></xref><offsets xml_i="12559" xml_f="13408" txt_i="5681" txt_f="6530">]. In brief, the anti-Aβ
antibodies 6E10 and 4G8 were separately coupled to magnetic beads. After washing
of the beads, the 4G8 and 6E10 coated beads were used in combination for
immunoprecipitation. After elution of the immune-purified Aβ peptides, analyte
detection was performed on an UltraFlextreme MALDI TOF/TOF instrument (Bruker
Daltonics, Bremen, Germany). For relative quantification of Aβ peptides, an
in-house developed MATLAB (Mathworks Inc. Natick, MA, USA) program was used. For
each peak the sum of the intensities for the three strongest isotopic signals was
calculated and normalized against the sum for all the Aβ peaks in the spectrum,
followed by averaging of results for separately determined duplicate samples. In
the 30-mg group, one sample, six hours post treatment, was omitted from further
analysis due to blood in the CSF.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="13440" xml_f="13456" txt_i="6532" txt_f="6548">Cell experiments</offsets></title><p><offsets xml_i="13467" xml_f="13482" txt_i="6549" txt_f="6564">SH-SY5Y cells [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="13515" xml_f="13517" txt_i="6564" txt_f="6566">19</offsets></xref><offsets xml_i="13524" xml_f="13920" txt_i="6566" txt_f="6962">]
obtained from the European Collection of Cell Cultures (ECACC 94030304), stably
expressing human APP, were maintained in Dulbecco’s modified Eagle’s medium F-12
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum,
L-glutamine and antibiotics. SH-SY5Y cells were treated with the BACE1-inhibitor
β-secretase inhibitor IV (Calbiochem, Merck, compound 3, Darmstadt, Germany)
[</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="13953" xml_f="13955" txt_i="6962" txt_f="6964">20</offsets></xref><offsets xml_i="13962" xml_f="14032" txt_i="6964" txt_f="7034">], LY2811376, or dimethyl
sulfoxide (DMSO) and incubated for 20 hours.</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="14064" xml_f="14097" txt_i="7036" txt_f="7069">Enzyme-linked immunosorbent assay</offsets></title><p><offsets xml_i="14108" xml_f="14132" txt_i="7070" txt_f="7094">For quantification of Aβ</offsets><sub><offsets xml_i="14137" xml_f="14141" txt_i="7094" txt_f="7098">5-40</offsets></sub><offsets xml_i="14147" xml_f="14154" txt_i="7098" txt_f="7105"> and
Aβ</offsets><sub><offsets xml_i="14159" xml_f="14162" txt_i="7105" txt_f="7108">5-x</offsets></sub><offsets xml_i="14168" xml_f="14231" txt_i="7108" txt_f="7171"> using ELISA, microtiter plates were coated with
10 μg/mL 2G3 [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="14264" xml_f="14266" txt_i="7171" txt_f="7173">21</offsets></xref><offsets xml_i="14273" xml_f="14283" txt_i="7173" txt_f="7183">]
(anti-Aβ</offsets><sub><offsets xml_i="14288" xml_f="14292" txt_i="7183" txt_f="7187">x-40</offsets></sub><offsets xml_i="14298" xml_f="14397" txt_i="7187" txt_f="7282">; epitope including valine at position 40,
Eli Lilly &amp; Company, Indianapolis, IN, USA) or 266 [</offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="14430" xml_f="14432" txt_i="7282" txt_f="7284">22</offsets></xref><offsets xml_i="14439" xml_f="14449" txt_i="7284" txt_f="7294">] (anti-Aβ</offsets><sub><offsets xml_i="14454" xml_f="14457" txt_i="7294" txt_f="7297">1-x</offsets></sub><offsets xml_i="14463" xml_f="14594" txt_i="7297" txt_f="7424">; epitope
13-28, Eli Lilly &amp; Company) overnight at 4°C. After blocking plates in 2%
bovine serum albumin (BSA), dilutions of Aβ</offsets><sub><offsets xml_i="14599" xml_f="14603" txt_i="7424" txt_f="7428">5-40</offsets></sub><offsets xml_i="14609" xml_f="14933" txt_i="7428" txt_f="7752"> standards
(Anaspec) and CSF samples were incubated on plates in 1% BSA, 0.55 M
guanidine-HCL, 5 mM Tris in phosphate buffered saline (PBS) with complete
ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor (Roche, Mannheim,
Germany) overnight at 4°C. After washing in PBS-0.05% Tween 20, biotinylated 5H5
(anti-Aβ</offsets><sub><offsets xml_i="14938" xml_f="14941" txt_i="7752" txt_f="7755">5-x</offsets></sub><offsets xml_i="14947" xml_f="15210" txt_i="7755" txt_f="8014">; epitope including arginine at position 5,
Eli Lilly &amp; Company) was used to detect the truncated Aβ beginning at the
arginine at position 5. The 5H5 monoclonal antibody was developed in mice
following standard methods and the specificity for the truncated
Aβ</offsets><sub><offsets xml_i="15215" xml_f="15218" txt_i="8014" txt_f="8017">5-x</offsets></sub><offsets xml_i="15224" xml_f="15476" txt_i="8017" txt_f="8269"> was investigated by acid urea gel (a technique that
separates Aβ peptides by mass and charge) and ELISA methods. Acid urea gel
separation of synthetic Aβ peptides followed by Western blotting with 5H5 revealed
complete selectivity for the truncated Aβ</offsets><sub><offsets xml_i="15481" xml_f="15485" txt_i="8269" txt_f="8273">5-42</offsets></sub><offsets xml_i="15491" xml_f="15521" txt_i="8273" txt_f="8303"> as compared
to full-length Aβ</offsets><sub><offsets xml_i="15526" xml_f="15530" txt_i="8303" txt_f="8307">1-42</offsets></sub><offsets xml_i="15536" xml_f="15752" txt_i="8307" txt_f="8523">. Additionally, acid urea gel/5H5
Western blotting analysis of human cortical tissue from multiple Alzheimer’s
subjects resulted in a single identifiable band that co-migrated at the same
position as the synthetic Aβ</offsets><sub><offsets xml_i="15757" xml_f="15761" txt_i="8523" txt_f="8527">5-42</offsets></sub><offsets xml_i="15767" xml_f="15863" txt_i="8527" txt_f="8623"> standard. Note, the
migration of the Aβ peptides in this gel system completely separates the
Aβ</offsets><sub><offsets xml_i="15868" xml_f="15872" txt_i="8623" txt_f="8627">5-42</offsets></sub><offsets xml_i="15878" xml_f="16041" txt_i="8627" txt_f="8790"> from all other Aβ peptides (truncated or
full-length). ELISA analyses to investigate the 5H5 epitope selectivity
demonstrated a 20,000-fold selectivity for the Aβ</offsets><sub><offsets xml_i="16046" xml_f="16049" txt_i="8790" txt_f="8793">5-x</offsets></sub><offsets xml_i="16055" xml_f="16098" txt_i="8793" txt_f="8836">
epitope versus the full-length peptide (Aβ</offsets><sub><offsets xml_i="16103" xml_f="16106" txt_i="8836" txt_f="8839">1-x</offsets></sub><offsets xml_i="16112" xml_f="16416" txt_i="8839" txt_f="9143">). Following
additional washes in PBS-0.05% Tween 20, plates were incubated with
streptavidin-horseradish peroxidase (HRP) (Biosource, San Diego, CA, USA) and
subsequently, 3,3´,5,5´-Tetramethylbenzzidine (TMB) (Sigma, St. Louis, MO, USA)
color development was monitored at 650 nm in a spectrophotometer.</offsets></p><p><offsets xml_i="16423" xml_f="16559" txt_i="9144" txt_f="9280">Quantification of CSF sAPPα and sAPPβ was conducted as described
previously and the results from these analyses have already published
[</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="16592" xml_f="16594" txt_i="9280" txt_f="9282">17</offsets></xref><offsets xml_i="16601" xml_f="16603" txt_i="9282" txt_f="9284">].</offsets></p></sec><sec id="Sec7"><title><offsets xml_i="16635" xml_f="16655" txt_i="9286" txt_f="9306">Statistical analysis</offsets></title><p><offsets xml_i="16666" xml_f="16821" txt_i="9307" txt_f="9462">The time series for each treatment were analyzed using Friedman’s
test (SPSS v13, Chicago, IL, USA). A dose-dependent effect was considered
significant if </offsets><italic><offsets xml_i="16829" xml_f="16830" txt_i="9462" txt_f="9463">P</offsets></italic><offsets xml_i="16839" xml_f="16860" txt_i="9463" txt_f="9481"> &lt;0.05 and if the </offsets><italic><offsets xml_i="16868" xml_f="16869" txt_i="9481" txt_f="9482">P</offsets></italic><offsets xml_i="16878" xml_f="17052" txt_i="9482" txt_f="9656">-value decreased with increasing dose. Association
analyses were performed by Spearman’s rank correlation and the correlation
coefficient is presented by spearman’s rho (rs).</offsets></p></sec></sec><sec id="Sec8" sec-type="results"><title><offsets xml_i="17109" xml_f="17116" txt_i="9659" txt_f="9666">Results</offsets></title><sec id="Sec9"><title><offsets xml_i="17146" xml_f="17242" txt_i="9667" txt_f="9763">LY2811376 induces a characteristic Aβ peptide pattern in a human-derived
neuroblastoma cell line</offsets></title><p><offsets xml_i="17253" xml_f="17522" txt_i="9764" txt_f="10033">As expected, SH-SY5Y cells treated with the BACE1-inhibitor
LY2811376 or BACE IV secreted less Aβ1-40 and Aβ1-42 to the cell medium while the
relative levels of Aβ5-40 (relative to the other Aβ peptides detected) increased,
as compared to vehicle-treated cells (Figure </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="17554" xml_f="17555" txt_i="10033" txt_f="10034">1</offsets></xref><offsets xml_i="17562" xml_f="17689" txt_i="10034" txt_f="10161">). These data clearly demonstrate that LY2811376 inhibits BACE1
activity and that the generation of Aβ5-40 is BACE independent.</offsets><fig id="Fig1"><label><offsets xml_i="17711" xml_f="17719" txt_i="10161" txt_f="10169">Figure 1</offsets></label><caption><p><offsets xml_i="17739" xml_f="17740" txt_i="10169" txt_f="10170">
</offsets><bold><offsets xml_i="17746" xml_f="17835" txt_i="10170" txt_f="10259">Mass spectra displaying the effect of treatment on
multiple Aβ species in cell media. (A)</offsets></bold><offsets xml_i="17842" xml_f="17859" txt_i="10259" txt_f="10276"> DMSO (vehicle),
</offsets><bold><offsets xml_i="17865" xml_f="17868" txt_i="10276" txt_f="10279">(B)</offsets></bold><offsets xml_i="17875" xml_f="17918" txt_i="10279" txt_f="10322"> 1.25 μM of the BACE1-inhibitor
LY2811376, </offsets><bold><offsets xml_i="17924" xml_f="17927" txt_i="10322" txt_f="10325">(C)</offsets></bold><offsets xml_i="17934" xml_f="17976" txt_i="10325" txt_f="10367"> 2.5 μM of the
BACE1-inhibitor LY2811376, </offsets><bold><offsets xml_i="17982" xml_f="17985" txt_i="10367" txt_f="10370">(D)</offsets></bold><offsets xml_i="17992" xml_f="18035" txt_i="10370" txt_f="10413"> 1.25 μM of
the BACE-inhibitor BACE IV and </offsets><bold><offsets xml_i="18041" xml_f="18044" txt_i="10413" txt_f="10416">(E)</offsets></bold><offsets xml_i="18051" xml_f="18222" txt_i="10416" txt_f="10587"> 2.5 μM
of the BACE-inhibitor BACE IV in media from SH-SY5Y cells. *Represent
unidentified peaks. Aβ, β-amyloid; BACE, β-site APP-cleaving enzyme; DMSO,
dimethyl sulfoide.</offsets></p></caption><graphic xlink:href="13195_2014_75_Fig1_HTML" id="MO1"></graphic></fig></p></sec><sec id="Sec10"><title><offsets xml_i="18340" xml_f="18485" txt_i="10590" txt_f="10735">The BACE1 inhibitor LY2811376 causes a relative reduction in CSF Aβ1-34 and
an increase in CSF Aβ5-40 in humans as reflected by mass spectrometry</offsets></title><p><offsets xml_i="18496" xml_f="18931" txt_i="10736" txt_f="11171">To evaluate if the BACE1-mediated changes described in exploratory
Aβ biomarker studies were translatable to humans, the CSF mass spectrometric Aβ
peptide pattern from untreated subjects was compared to the pattern from subjects
treated with different concentrations of the BACE1-inhibitor LY2811376.
Representative CSF Aβ peptide mass spectra from a subject before treatment and
36 hours after drug administration are shown in Figure </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="18963" xml_f="18964" txt_i="11171" txt_f="11172">2</offsets></xref><offsets xml_i="18971" xml_f="19243" txt_i="11172" txt_f="11444">A-D. Although barely detectable versus background before
treatment, BACE1 inhibition increased the mass spectrometric signal for Aβ5-40
while the signal corresponding to Aβ1-34 decreased. In total, 13 Aβ species
ranging from Aβ1-15 up to Aβ1-42 were reproducibly detected.</offsets><fig id="Fig2"><label><offsets xml_i="19265" xml_f="19273" txt_i="11444" txt_f="11452">Figure 2</offsets></label><caption><p><offsets xml_i="19293" xml_f="19294" txt_i="11452" txt_f="11453">
</offsets><bold><offsets xml_i="19300" xml_f="19447" txt_i="11453" txt_f="11600">Mass spectra displaying multiple Aβ species
recovered from human CSF specimens by immunoprecipitation with the
anti-Aβ antibodies 6E10 and 4G8. (A)</offsets></bold><offsets xml_i="19454" xml_f="19470" txt_i="11600" txt_f="11616"> Pre-treatment, </offsets><bold><offsets xml_i="19476" xml_f="19479" txt_i="11616" txt_f="11619">(B)</offsets></bold><offsets xml_i="19486" xml_f="19491" txt_i="11619" txt_f="11624"> 12, </offsets><bold><offsets xml_i="19497" xml_f="19500" txt_i="11624" txt_f="11627">(C)</offsets></bold><offsets xml_i="19507" xml_f="19516" txt_i="11627" txt_f="11636"> 24,
and </offsets><bold><offsets xml_i="19522" xml_f="19525" txt_i="11636" txt_f="11639">(D)</offsets></bold><offsets xml_i="19532" xml_f="19749" txt_i="11639" txt_f="11856"> 36 hours post treatment with
90 mg of LY2811376. The right-hand panels are magnified spectra displaying
the increase in Aβ5-40 and decrease in Aβ1-34 in response to treatment.
Aβ, β-amyloid; CSF, cerebrospinal fluid.</offsets></p></caption><graphic xlink:href="13195_2014_75_Fig2_HTML" id="MO2"></graphic></fig></p><p><offsets xml_i="19841" xml_f="19964" txt_i="11858" txt_f="11981">The BACE1 inhibitor LY2811376 dose-dependently reduced Aβ1-34
relative to baseline with a nadir of 42% in the 30-mg group (</offsets><italic><offsets xml_i="19972" xml_f="19973" txt_i="11981" txt_f="11982">P</offsets></italic><offsets xml_i="19982" xml_f="20019" txt_i="11982" txt_f="12019"> =0.002) and 57% in the 90-mg group (</offsets><italic><offsets xml_i="20027" xml_f="20028" txt_i="12019" txt_f="12020">P</offsets></italic><offsets xml_i="20037" xml_f="20106" txt_i="12020" txt_f="12086"> &lt;0.001) respectively, 24 hours after drug
administration (Figure </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="20138" xml_f="20139" txt_i="12086" txt_f="12087">3</offsets></xref><offsets xml_i="20146" xml_f="20270" txt_i="12087" txt_f="12211">A). By contrast,
LY2811376 dose-dependently increased Aβ5-40 to a maximum relative to baseline
after 18 hours in the 30-mg (</offsets><italic><offsets xml_i="20278" xml_f="20279" txt_i="12211" txt_f="12212">P</offsets></italic><offsets xml_i="20288" xml_f="20312" txt_i="12212" txt_f="12236"> =0.213) and the
90-mg (</offsets><italic><offsets xml_i="20320" xml_f="20321" txt_i="12236" txt_f="12237">P</offsets></italic><offsets xml_i="20330" xml_f="20371" txt_i="12237" txt_f="12275"> &lt;0.001) groups, respectively
(Figure </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="20403" xml_f="20404" txt_i="12275" txt_f="12276">3</offsets></xref><offsets xml_i="20411" xml_f="20705" txt_i="12276" txt_f="12570">B). The mass spectrometric
signal for Aβ5-40 in the placebo group was below the limit of detection while in
the 90-mg treatment group the signal-to-noise ratio was 4 to 5. At 36 hours
post-treatment, both Aβ5-40 and Aβ1-34 had started to return towards baseline
levels in both treatment groups.</offsets><fig id="Fig3"><label><offsets xml_i="20727" xml_f="20735" txt_i="12570" txt_f="12578">Figure 3</offsets></label><caption><p><offsets xml_i="20755" xml_f="20756" txt_i="12578" txt_f="12579">
</offsets><bold><offsets xml_i="20762" xml_f="20931" txt_i="12579" txt_f="12748">The relative mass spectrometric change from baseline
and ELISA-derived concentrations in response to a single dose of 30 mg
or 90 mg of the BACE inhibitor LY2811376. (A)</offsets></bold><offsets xml_i="20938" xml_f="21025" txt_i="12748" txt_f="12835"> Mass
spectrometric change in the CSF Aβ1-34 time course after LY2811376
treatment and </offsets><bold><offsets xml_i="21031" xml_f="21034" txt_i="12835" txt_f="12838">(B)</offsets></bold><offsets xml_i="21041" xml_f="21125" txt_i="12838" txt_f="12922"> mass spectrometric
change in the CSF Aβ5-40 time course after LY2811376 treatment. </offsets><bold><offsets xml_i="21131" xml_f="21134" txt_i="12922" txt_f="12925">(C)</offsets></bold><offsets xml_i="21141" xml_f="21231" txt_i="12925" txt_f="13015"> ELISA-derived concentrations of the CSF
Aβ5-40 time course after LY2811376 treatment and </offsets><bold><offsets xml_i="21237" xml_f="21240" txt_i="13015" txt_f="13018">(D)</offsets></bold><offsets xml_i="21247" xml_f="21518" txt_i="13018" txt_f="13289"> ELISA-derived concentrations of the CSF Aβ5-X time
course after LY2811376 treatment. Open circles represent placebo, grey
squares represent treatment with 30 mg LY2811376 and closed triangles
represent treatment with 90 mg LY2811376. Data are presented as mean ± SD
and </offsets><italic><offsets xml_i="21526" xml_f="21527" txt_i="13289" txt_f="13290">n</offsets></italic><offsets xml_i="21536" xml_f="21666" txt_i="13290" txt_f="13420"> =6 for both graphs. Aβ,
β-amyloid; BACE, β-site APP-cleaving enzyme; CSF, cerebrospinal fluid; n,
number; SD, standard deviation.</offsets></p></caption><graphic xlink:href="13195_2014_75_Fig3_HTML" id="MO3"></graphic></fig></p></sec><sec id="Sec11"><title><offsets xml_i="21784" xml_f="21902" txt_i="13423" txt_f="13541">The BACE1-inhibitor LY2811376 causes an absolute increase in both CSF
Aβ5-40 and Aβ5-X in humans as reflected by ELISA</offsets></title><p><offsets xml_i="21913" xml_f="22330" txt_i="13542" txt_f="13959">The increase in Aβ5-40 detected by mass spectrometry in response to
treatment with the BACE1 inhibitor LY2811376 was further confirmed by a
proprietary ELISA. While the placebo concentrations were low, in the range of
approximately 100 pg/mL and approximately 50 pg/mL for Aβ5-X and Aβ5-40,
respectively, there were clear increases in the LY2811376 high dose (90 mg) group
over time for both Aβ5-X and Aβ5-40 (Figure </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="22362" xml_f="22363" txt_i="13959" txt_f="13960">3</offsets></xref><offsets xml_i="22370" xml_f="22437" txt_i="13960" txt_f="14027">C-D) of which the increase in Aβ5-X was statistically
significant (</offsets><italic><offsets xml_i="22445" xml_f="22446" txt_i="14027" txt_f="14028">P</offsets></italic><offsets xml_i="22455" xml_f="22669" txt_i="14028" txt_f="14242"> =0.02). The ELISA-determined
concentrations of Aβ5-42 were too low to yield an accurate assessment, which is in
agreement with the mass spectrometric data where Aβ5-42 could not be detected in
any treatment group.</offsets></p><p><offsets xml_i="22676" xml_f="22792" txt_i="14243" txt_f="14359">In the 90-mg dose group, there was a compensatory increase in the
concentrations of both Aβ5-X and sAPPα (rs =0.94, </offsets><italic><offsets xml_i="22800" xml_f="22801" txt_i="14359" txt_f="14360">P</offsets></italic><offsets xml_i="22810" xml_f="22880" txt_i="14360" txt_f="14430"> =0.02) while Aβ5-X was negatively correlated with sAPPβ
(rs = -0.89, </offsets><italic><offsets xml_i="22888" xml_f="22889" txt_i="14430" txt_f="14431">P</offsets></italic><offsets xml_i="22898" xml_f="22929" txt_i="14431" txt_f="14462"> =0.03) as presented in
Figure </offsets><xref rid="Fig4" ref-type="fig"><offsets xml_i="22961" xml_f="22962" txt_i="14462" txt_f="14463">4</offsets></xref><offsets xml_i="22969" xml_f="23105" txt_i="14463" txt_f="14599">A,B. There were no correlations
between the two peptides starting at amino acid five and sAPPα or sAPPβ in the
30-mg and placebo groups.</offsets><fig id="Fig4"><label><offsets xml_i="23127" xml_f="23135" txt_i="14599" txt_f="14607">Figure 4</offsets></label><caption><p><offsets xml_i="23155" xml_f="23156" txt_i="14607" txt_f="14608">
</offsets><bold><offsets xml_i="23162" xml_f="23245" txt_i="14608" txt_f="14691">Correlation between Aβ5-X and (A) sAPPα and (B)
sAPPβ in the 90-mg treatment group.</offsets></bold><offsets xml_i="23252" xml_f="23299" txt_i="14691" txt_f="14738"> Aβ, β-amyloid; APP,
amyloid precursor protein.</offsets></p></caption><graphic xlink:href="13195_2014_75_Fig4_HTML" id="MO4"></graphic></fig></p></sec></sec><sec id="Sec12" sec-type="discussion"><title><offsets xml_i="23445" xml_f="23455" txt_i="14742" txt_f="14752">Discussion</offsets></title><p><offsets xml_i="23466" xml_f="23664" txt_i="14753" txt_f="14951">In the present study, we show marked effects on CSF Aβ5-40 (which
increases) and Aβ1-34 (which decreases) in response to BACE1 inhibitor treatment.
These findings confirm earlier pre-clinical data [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="23696" xml_f="23697" txt_i="14951" txt_f="14952">9</offsets></xref><offsets xml_i="23704" xml_f="24096" txt_i="14952" txt_f="15344">] and suggest that CSF Aβ5-40 and Aβ1-34 may be useful
pharmacodynamic markers for assessing the biochemical effects of BACE-1 inhibitors
in the CNS in clinical trials. The relatively low concentrations of both Aβ5-40 and
Aβ5-X fit previous findings with comparable percentage reductions in Aβ1-40 versus
AβX-40 and Aβ1-42 versus AβX-42 in dog CSF following oral administration of
LY2811376 [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="24129" xml_f="24131" txt_i="15344" txt_f="15346">17</offsets></xref><offsets xml_i="24138" xml_f="24140" txt_i="15346" txt_f="15348">].</offsets></p><p><offsets xml_i="24147" xml_f="24826" txt_i="15349" txt_f="16028">Since the discovery and molecular cloning of BACE1 in 1999 by several
independent groups, this enzyme has been a tempting target for pharmacological
lowering of cerebral Aβ levels with the intent of treating or preventing AD. To
date, there are only a few reports of BACE1 inhibitors that have demonstrated
sufficient access to the brain. In a recent paper, oral administration of the
non-peptidic BACE1 inhibitor LY2811376 to healthy subjects (same patients as
included in the present study) dose-dependently lowered CSF Aβ1-40, Aβ1-42 and sAPPβ
levels and dose-dependently increased CSF sAPPα, providing evidence of desirable
central pharmacodynamic effects on APP processing [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="24859" xml_f="24861" txt_i="16028" txt_f="16030">17</offsets></xref><offsets xml_i="24868" xml_f="25016" txt_i="16030" txt_f="16178">]. In another study, a therapeutic antibody that reduces BACE1
activity was used, resulting in lowered CNS Aβ concentrations in preclinical models
[</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="25049" xml_f="25051" txt_i="16178" txt_f="16180">23</offsets></xref><offsets xml_i="25058" xml_f="25212" txt_i="16180" txt_f="16334">]. Whether this approach can be
translated to humans and if other Aβ species besides Aβ1-40 are affected in response
to treatment remain to be elucidated.</offsets></p><p><offsets xml_i="25219" xml_f="25468" txt_i="16335" txt_f="16584">LY2811376 treatment consistently increased CSF levels of Aβ5-40. The
increase of Aβ5-40 in response to BACE1 inhibition clearly suggests that production
of Aβ peptides starting at position 5 is formed via a BACE1-independent
APP-processing pathway [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="25500" xml_f="25501" txt_i="16584" txt_f="16585">9</offsets></xref><offsets xml_i="25508" xml_f="25692" txt_i="16585" txt_f="16769">]. In agreement
with this, it has been suggested that inhibition of BACE1 might be linked to a
distinct processing of APP between Phe4 and Arg5 mediated by α-secretase-like
proteases [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="25725" xml_f="25727" txt_i="16769" txt_f="16771">24</offsets></xref><offsets xml_i="25734" xml_f="25853" txt_i="16771" txt_f="16890">]. Other enzymes which
might cleave in this region of Aβ include α-chymotrypsin, myelin basic protein and
protease IV [</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="25886" xml_f="25888" txt_i="16890" txt_f="16892">25</offsets></xref><offsets xml_i="25895" xml_f="25956" txt_i="16892" txt_f="16953">]. However, while these
enzymes have been shown to cleave Aβ </offsets><italic><offsets xml_i="25964" xml_f="25972" txt_i="16953" txt_f="16961">in vitro</offsets></italic><offsets xml_i="25981" xml_f="26088" txt_i="16961" txt_f="17068">,
data from the CNS showing which enzyme that cleaves between Phe4 and Arg5 inhibition
of BACE1 is lacking.</offsets></p><p><offsets xml_i="26095" xml_f="26198" txt_i="17069" txt_f="17172">Recently, we showed in pre-clinical models that CSF Aβ1-34 is a
sensitive marker for BACE1 inhibition [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="26230" xml_f="26231" txt_i="17172" txt_f="17173">9</offsets></xref><offsets xml_i="26238" xml_f="26384" txt_i="17173" txt_f="17319">]. We have previously shown, in two independent clinical trials,
that CSF Aβ1-34 is a pharmacodynamic marker of γ-secretase inhibition in humans
[</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="26417" xml_f="26419" txt_i="17319" txt_f="17321">14</offsets></xref><offsets xml_i="26426" xml_f="26427" txt_i="17321" txt_f="17322">,</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="26460" xml_f="26462" txt_i="17322" txt_f="17324">15</offsets></xref><offsets xml_i="26469" xml_f="26662" txt_i="17324" txt_f="17517">] and here we show for the first time that it is also a marker of
BACE1 inhibition in humans. It has been shown that the cleavage between Leu34 and
Met35 depends on both BACE1 and γ-secretase [</offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="26695" xml_f="26697" txt_i="17517" txt_f="17519">26</offsets></xref><offsets xml_i="26704" xml_f="26705" txt_i="17519" txt_f="17520">,</offsets><xref ref-type="bibr" rid="CR27"><offsets xml_i="26738" xml_f="26740" txt_i="17520" txt_f="17522">27</offsets></xref><offsets xml_i="26747" xml_f="27057" txt_i="17522" txt_f="17832">]. Thus, Aβ1-34
is an intriguing peptide to follow in clinical trials of BACE1 inhibitors since
cleavages at position 1 and position 34 both depend on BACE. It is also possible
that Aβ1-34 is more stable than Aβ1-42, as it is less hydrophobic and may thereby be
less prone to preanalytical confounding factors.</offsets></p><p><offsets xml_i="27064" xml_f="27100" txt_i="17833" txt_f="17869">Aβ5-40 has been found in AD brains [</offsets><xref ref-type="bibr" rid="CR28"><offsets xml_i="27133" xml_f="27135" txt_i="17869" txt_f="17871">28</offsets></xref><offsets xml_i="27142" xml_f="27380" txt_i="17871" txt_f="18109">], but the exact role of this Aβ species in AD pathogenesis (and
normal physiology), if any, is unknown and we propose that further studies of
biological functions and how the peptide might be relevant to AD pathophysiology are
warranted.</offsets></p><p><offsets xml_i="27387" xml_f="27838" txt_i="18110" txt_f="18561">We found a positive correlation between sAPPα and Aβ5-X. This
correlation may reflect a compensatory increase in APP cleavage at the α-site and
between amino acid 4/5, or that there might be more substrate for these enzymes due
to inhibition of BACE. We also found a negative correlation between sAPPβ and Aβ5-X,
clearly showing that while the amyloidogenic pathway is affected, the (as yet)
unknown enzyme generating Aβ5-X cleaves its substrate more.</offsets></p><p><offsets xml_i="27845" xml_f="28613" txt_i="18562" txt_f="19330">There are several non-quantitative aspects of HI-MS. The relative
quantification using mass spectrometry cannot be interpreted as a direct reflection
of an absolute or relative abundance. However, in the present study we have verified
the mass spectrometric data showing increased relative levels of Aβ5-40 with a
proprietary ELISA showing increased concentrations of both Aβ5-40 and Aβ5-X in
response to inhibition of BACE1. What also should be noted is that the ELISA
measures an absolute concentration while MS reports the relative change of Aβ5-40
relative to all other Aβ peptides detected in the same spectra. A previous study on
the same patients as those included in the present study showed a marked decrease in
CSF Aβ1-40 in response to LY2811376 treatment [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="28646" xml_f="28648" txt_i="19330" txt_f="19332">17</offsets></xref><offsets xml_i="28655" xml_f="28948" txt_i="19332" txt_f="19625">]. Due to the relative quantification used in the present study,
we were not able to measure the expected decrease. However, by implementing
isotopically-labelled Aβ peptides for each peptide of interest, relative small
changes in response to treatment should be possible to detect with HI-MS.</offsets></p></sec><sec id="Sec13" sec-type="conclusion"><title><offsets xml_i="29003" xml_f="29014" txt_i="19627" txt_f="19638">Conclusions</offsets></title><p><offsets xml_i="29025" xml_f="29508" txt_i="19639" txt_f="20122">In summary, our results confirm that CSF Aβ1-34 may be useful in
clinical trials on BACE1 inhibitors to monitor target engagement. By independent
measurement techniques, we show that BACE1 inhibition in humans is associated with
APP-processing into N-terminally truncated Aβ peptides via a BACE1-independent
pathway. The data presented also provide evidence for CSF Aβ1-34 and Aβ5-40 as
translatable pharmacodynamic markers for BACE1-inhibition from cell and animal
models to humans.</offsets></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>AD</term><def><p>Alzheimer’s disease</p></def></def-item><def-item><term>APP</term><def><p>amyloid precursor protein</p></def></def-item><def-item><term>Aβ</term><def><p>β-amyloid</p></def></def-item><def-item><term>BACE 1</term><def><p>β-site APP-cleaving enzyme 1</p></def></def-item><def-item><term>BSA</term><def><p>bovine serum albumin</p></def></def-item><def-item><term>CNS</term><def><p>central nervous system</p></def></def-item><def-item><term>CSF</term><def><p>cerebrospinal fluid</p></def></def-item><def-item><term>ELISA</term><def><p>enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>HI-MS</term><def><p>hybrid immunoaffinity-mass spectrometry</p></def></def-item><def-item><term>MALDI-TOF</term><def><p>matrix-assisted laser desorption/ionization
time-of-flight</p></def></def-item><def-item><term>MS</term><def><p>mass spectrometry</p></def></def-item><def-item><term>PBS</term><def><p>phosphate-buffered saline</p></def></def-item><def-item><term>TMB</term><def><p>3,3´,5,5´-Tetramethylbenzzidine</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p></p></fn><fn><p><bold>Authors’ contributions</bold></p><p>EP planned the experimental design, analyzed and interpreted mass
spectrometric data and drafted the manuscript. RAD designed and managed
implementation of the clinical trial and interpreted data. UA analyzed and
interpreted data. NM analyzed and interpreted data. AW acquired mass spectrometric
data and interpreted results. MO performed cell studies and interpreted results. RBD
designed the ELISA methods and generated the ELISA data and interpreted results. MMR
designed the ELISA methods, generated the ELISA data and interpreted results. HZ
analyzed and interpreted data. PCM analyzed and interpreted data. KB planned the
experimental design, analyzed and interpreted data. All authors revised the
manuscript critically for important intellectual content. All authors read and
approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors wish to thank Jayne Talbot for operational support of this
research and review of this manuscript.</p><sec id="d30e790"><title>Funding</title><p>The study was supported by the Lundbeck Foundation, the Swedish
Research Council, Swedish State Support for Clinical Research, Stiftelsen
Psykiatriska Forskningsfonden, the Wolfson Foundation, Stiftelsen Gamla
Tjänarinnor, Magn. Bergvalls Stiftelse, Gun och Bertil Stohnes Stiftelse, Uppsala
Universitets Medicinska Fakultet stiftelse för psykiatrisk och neurologisk
forskning, the Swedish Brain Fund, the Alzheimer Foundation, Sweden, the Dementia
Association, Sweden, and Eli Lilly and Company.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glenner</surname><given-names>GG</given-names></name><name><surname>Wong</surname><given-names>CW</given-names></name></person-group><article-title>Alzheimer’s disease: initial report of the
purification and characterization of a novel cerebrovascular amyloid
protein</article-title><source>Biochem Biophys Res Commun</source><year>1984</year><volume>120</volume><fpage>885</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(84)80190-4</pub-id><pub-id pub-id-type="pmid">6375662</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Allsop</surname><given-names>D</given-names></name></person-group><article-title>Amyloid deposition as the central event in the
aetiology of Alzheimer’s disease</article-title><source>Trends Pharmacol Sci</source><year>1991</year><volume>12</volume><fpage>383</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/0165-6147(91)90609-V</pub-id><pub-id pub-id-type="pmid">1763432</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassar</surname><given-names>R</given-names></name><name><surname>Kandalepas</surname><given-names>PC</given-names></name></person-group><article-title>The beta-secretase enzyme BACE1 as a therapeutic
target for Alzheimer’s disease</article-title><source>Alzheimers Res Ther</source><year>2011</year><volume>3</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/alzrt82</pub-id><pub-id pub-id-type="pmid">21639952</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>H</given-names></name><name><surname>Fluhrer</surname><given-names>R</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name></person-group><article-title>Intramembrane proteolysis by
gamma-secretase</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>29627</fpage><lpage>29631</lpage><pub-id pub-id-type="doi">10.1074/jbc.R800010200</pub-id><pub-id pub-id-type="pmid">18650432</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Citron</surname><given-names>M</given-names></name></person-group><article-title>Alzheimer’s disease: strategies for disease
modification</article-title><source>Nat Rev Drug Discov</source><year>2010</year><volume>9</volume><fpage>387</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1038/nrd2896</pub-id><pub-id pub-id-type="pmid">20431570</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Weiner</surname><given-names>M</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name></person-group><article-title>Cerebrospinal fluid and plasma biomarkers in Alzheimer
disease</article-title><source>Nat Rev Neurol</source><year>2010</year><volume>6</volume><fpage>131</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2010.4</pub-id><pub-id pub-id-type="pmid">20157306</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Ringman</surname><given-names>JM</given-names></name><name><surname>Buerger</surname><given-names>K</given-names></name><name><surname>Daborg</surname><given-names>J</given-names></name><name><surname>Buchhave</surname><given-names>P</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Harmsen</surname><given-names>A</given-names></name><name><surname>Gustavsson</surname><given-names>MK</given-names></name><name><surname>Hanse</surname><given-names>E</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name></person-group><article-title>Distinct cerebrospinal fluid amyloid beta peptide
signatures in sporadic and PSEN1 A431E-associated familial Alzheimer’s
disease</article-title><source>Mol Neurodegener</source><year>2010</year><volume>5</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1750-1326-5-2</pub-id><pub-id pub-id-type="pmid">20145736</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pannee</surname><given-names>J</given-names></name><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Oppermann</surname><given-names>M</given-names></name><name><surname>Atkins</surname><given-names>A</given-names></name><name><surname>Hornshaw</surname><given-names>M</given-names></name><name><surname>Zegers</surname><given-names>I</given-names></name><name><surname>Hojrup</surname><given-names>P</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Gobom</surname><given-names>J</given-names></name></person-group><article-title>A Selected Reaction Monitoring (SRM)-based method for
absolute quantification of Abeta38, Abeta40, and Abeta42 in cerebrospinal fluid
of Alzheimer’s disease patients and healthy controls</article-title><source>J Alzheimers Dis</source><year>2013</year><volume>33</volume><fpage>1021</fpage><lpage>1032</lpage><pub-id pub-id-type="pmid">23076076</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattsson</surname><given-names>N</given-names></name><name><surname>Rajendran</surname><given-names>L</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Gustavsson</surname><given-names>M</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Olsson</surname><given-names>M</given-names></name><name><surname>Brinkmalm</surname><given-names>G</given-names></name><name><surname>Lundkvist</surname><given-names>J</given-names></name><name><surname>Jacobson</surname><given-names>LH</given-names></name><name><surname>Perrot</surname><given-names>L</given-names></name><name><surname>Neumann</surname><given-names>U</given-names></name><name><surname>Borghys</surname><given-names>H</given-names></name><name><surname>Mercken</surname><given-names>M</given-names></name><name><surname>Dhuyvetter</surname><given-names>D</given-names></name><name><surname>Jeppsson</surname><given-names>F</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Portelius</surname><given-names>E</given-names></name></person-group><article-title>BACE1 inhibition induces a specific cerebrospinal
fluid beta-amyloid pattern that identifies drug effects in the central nervous
system</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e31084</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0031084</pub-id><pub-id pub-id-type="pmid">22328928</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Price</surname><given-names>E</given-names></name><name><surname>Brinkmalm</surname><given-names>G</given-names></name><name><surname>Stiteler</surname><given-names>M</given-names></name><name><surname>Olsson</surname><given-names>M</given-names></name><name><surname>Persson</surname><given-names>R</given-names></name><name><surname>Westman-Brinkmalm</surname><given-names>A</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Simon</surname><given-names>AJ</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name></person-group><article-title>A novel pathway for amyloid precursor protein
processing</article-title><source>Neurobiol Aging</source><year>2011</year><volume>32</volume><fpage>1090</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2009.06.002</pub-id><pub-id pub-id-type="pmid">19604603</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>JJ</given-names></name><name><surname>Wildsmith</surname><given-names>KR</given-names></name><name><surname>Gilberto</surname><given-names>DB</given-names></name><name><surname>Holahan</surname><given-names>MA</given-names></name><name><surname>Kinney</surname><given-names>GG</given-names></name><name><surname>Mathers</surname><given-names>PD</given-names></name><name><surname>Michener</surname><given-names>MS</given-names></name><name><surname>Price</surname><given-names>EA</given-names></name><name><surname>Shearman</surname><given-names>MS</given-names></name><name><surname>Simon</surname><given-names>AJ</given-names></name><name><surname>Wang</surname><given-names>JX</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Yarasheski</surname><given-names>KE</given-names></name><name><surname>Bateman</surname><given-names>RJ</given-names></name></person-group><article-title>Acute gamma-secretase inhibition of nonhuman primate
CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta
production to alternative APP fragments without amyloid-beta
rebound</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>6743</fpage><lpage>6750</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1381-10.2010</pub-id><pub-id pub-id-type="pmid">20463236</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Van Broeck</surname><given-names>B</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Gustavsson</surname><given-names>MK</given-names></name><name><surname>Mercken</surname><given-names>M</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Borghys</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name></person-group><article-title>Acute effect on the Abeta isoform pattern in CSF in
response to gamma-secretase modulator and inhibitor treatment in
dogs</article-title><source>J Alzheimers Dis</source><year>2010</year><volume>21</volume><fpage>1005</fpage><lpage>1012</lpage><pub-id pub-id-type="pmid">20634579</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>PH</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Dislich</surname><given-names>B</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Zeitschel</surname><given-names>U</given-names></name><name><surname>Ellwart</surname><given-names>JW</given-names></name><name><surname>Kremmer</surname><given-names>E</given-names></name><name><surname>Rossner</surname><given-names>S</given-names></name><name><surname>Lichtenthaler</surname><given-names>SF</given-names></name></person-group><article-title>ADAM10 is the physiologically relevant, constitutive
alpha-secretase of the amyloid precursor protein in primary
neurons</article-title><source>EMBO J</source><year>2010</year><volume>29</volume><fpage>3020</fpage><lpage>3032</lpage><pub-id pub-id-type="doi">10.1038/emboj.2010.167</pub-id><pub-id pub-id-type="pmid">20676056</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coric</surname><given-names>V</given-names></name><name><surname>van Dyck</surname><given-names>CH</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Brody</surname><given-names>M</given-names></name><name><surname>Richter</surname><given-names>RW</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Thein</surname><given-names>S</given-names></name><name><surname>Shiovitz</surname><given-names>T</given-names></name><name><surname>Pilcher</surname><given-names>G</given-names></name><name><surname>Colby</surname><given-names>S</given-names></name><name><surname>Rollin</surname><given-names>L</given-names></name><name><surname>Dockens</surname><given-names>R</given-names></name><name><surname>Pachai</surname><given-names>C</given-names></name><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Soares</surname><given-names>H</given-names></name><name><surname>Albright</surname><given-names>C</given-names></name><name><surname>Feldman</surname><given-names>HH</given-names></name><name><surname>Berman</surname><given-names>RM</given-names></name></person-group><article-title>Safety and tolerability of the gamma-secretase
inhibitor avagacestat in a phase 2 study of mild to moderate alzheimer
disease</article-title><source>Arch Neurol</source><year>2012</year><volume>69</volume><fpage>1430</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2012.2194</pub-id><pub-id pub-id-type="pmid">22892585</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Dean</surname><given-names>RA</given-names></name><name><surname>Gustavsson</surname><given-names>MK</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Siemers</surname><given-names>E</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name></person-group><article-title>A novel Abeta isoform pattern in CSF reflects
gamma-secretase inhibition in Alzheimer disease</article-title><source>Alzheimers Res Ther</source><year>2010</year><volume>2</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/alzrt30</pub-id><pub-id pub-id-type="pmid">20350302</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Dean</surname><given-names>RA</given-names></name><name><surname>Marcil</surname><given-names>A</given-names></name><name><surname>Bourgeois</surname><given-names>P</given-names></name><name><surname>Nutu</surname><given-names>M</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Siemers</surname><given-names>E</given-names></name><name><surname>Mawuenyega</surname><given-names>KG</given-names></name><name><surname>Sigurdson</surname><given-names>WC</given-names></name><name><surname>May</surname><given-names>PC</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Bateman</surname><given-names>RJ</given-names></name></person-group><article-title>Amyloid-beta(1-15/16) as a marker for gamma-secretase
inhibition in Alzheimer’s disease</article-title><source>J Alzheimers Dis</source><year>2012</year><volume>31</volume><fpage>335</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">22531418</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>May</surname><given-names>PC</given-names></name><name><surname>Dean</surname><given-names>RA</given-names></name><name><surname>Lowe</surname><given-names>SL</given-names></name><name><surname>Martenyi</surname><given-names>F</given-names></name><name><surname>Sheehan</surname><given-names>SM</given-names></name><name><surname>Boggs</surname><given-names>LN</given-names></name><name><surname>Monk</surname><given-names>SA</given-names></name><name><surname>Mathes</surname><given-names>BM</given-names></name><name><surname>Mergott</surname><given-names>DJ</given-names></name><name><surname>Watson</surname><given-names>BM</given-names></name><name><surname>Stout</surname><given-names>SL</given-names></name><name><surname>Timm</surname><given-names>DE</given-names></name><name><surname>Smith Labell</surname><given-names>E</given-names></name><name><surname>Gonzales</surname><given-names>CR</given-names></name><name><surname>Nakano</surname><given-names>M</given-names></name><name><surname>Jhee</surname><given-names>SS</given-names></name><name><surname>Yen</surname><given-names>M</given-names></name><name><surname>Ereshefsky</surname><given-names>L</given-names></name><name><surname>Lindstrom</surname><given-names>TD</given-names></name><name><surname>Calligaro</surname><given-names>DO</given-names></name><name><surname>Cocke</surname><given-names>PJ</given-names></name><name><surname>Greg Hall</surname><given-names>D</given-names></name><name><surname>Friedrich</surname><given-names>S</given-names></name><name><surname>Citron</surname><given-names>M</given-names></name><name><surname>Audia</surname><given-names>JE</given-names></name></person-group><article-title>Robust central reduction of amyloid-beta in humans
with an orally available, non-peptidic beta-secretase inhibitor</article-title><source>J Neurosci</source><year>2011</year><volume>31</volume><fpage>16507</fpage><lpage>16516</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3647-11.2011</pub-id><pub-id pub-id-type="pmid">22090477</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Tran</surname><given-names>AJ</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Persson</surname><given-names>R</given-names></name><name><surname>Brinkmalm</surname><given-names>G</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Westman-Brinkmalm</surname><given-names>A</given-names></name></person-group><article-title>Characterization of amyloid beta peptides in
cerebrospinal fluid by an automated immunoprecipitation procedure followed by
mass spectrometry</article-title><source>J Proteome Res</source><year>2007</year><volume>6</volume><fpage>4433</fpage><lpage>4439</lpage><pub-id pub-id-type="doi">10.1021/pr0703627</pub-id><pub-id pub-id-type="pmid">17927230</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biedler</surname><given-names>JL</given-names></name><name><surname>Roffler-Tarlov</surname><given-names>S</given-names></name><name><surname>Schachner</surname><given-names>M</given-names></name><name><surname>Freedman</surname><given-names>LS</given-names></name></person-group><article-title>Multiple neurotransmitter synthesis by human
neuroblastoma cell lines and clones</article-title><source>Cancer Res</source><year>1978</year><volume>38</volume><fpage>3751</fpage><lpage>3757</lpage><pub-id pub-id-type="pmid">29704</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stachel</surname><given-names>SJ</given-names></name><name><surname>Coburn</surname><given-names>CA</given-names></name><name><surname>Steele</surname><given-names>TG</given-names></name><name><surname>Jones</surname><given-names>KG</given-names></name><name><surname>Loutzenhiser</surname><given-names>EF</given-names></name><name><surname>Gregro</surname><given-names>AR</given-names></name><name><surname>Rajapakse</surname><given-names>HA</given-names></name><name><surname>Lai</surname><given-names>MT</given-names></name><name><surname>Crouthamel</surname><given-names>MC</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Tugusheva</surname><given-names>K</given-names></name><name><surname>Lineberger</surname><given-names>JE</given-names></name><name><surname>Pietrak</surname><given-names>BL</given-names></name><name><surname>Espeseth</surname><given-names>AS</given-names></name><name><surname>Shi</surname><given-names>XP</given-names></name><name><surname>Chen-Dodson</surname><given-names>E</given-names></name><name><surname>Holloway</surname><given-names>MK</given-names></name><name><surname>Munshi</surname><given-names>S</given-names></name><name><surname>Simon</surname><given-names>AJ</given-names></name><name><surname>Kuo</surname><given-names>L</given-names></name><name><surname>Vacca</surname><given-names>JP</given-names></name></person-group><article-title>Structure-based design of potent and selective
cell-permeable inhibitors of human beta-secretase (BACE-1)</article-title><source>J Med Chem</source><year>2004</year><volume>47</volume><fpage>6447</fpage><lpage>6450</lpage><pub-id pub-id-type="doi">10.1021/jm049379g</pub-id><pub-id pub-id-type="pmid">15588077</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson-Wood</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Motter</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Gordon</surname><given-names>G</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Gordon</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><name><surname>Games</surname><given-names>D</given-names></name><name><surname>Lieberburg</surname><given-names>I</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>McConlogue</surname><given-names>L</given-names></name></person-group><article-title>Amyloid precursor protein processing and A beta42
deposition in a transgenic mouse model of Alzheimer disease</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><fpage>1550</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.4.1550</pub-id><pub-id pub-id-type="pmid">9037091</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Vigo-Pelfrey</surname><given-names>C</given-names></name><name><surname>Esch</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Dovey</surname><given-names>H</given-names></name><name><surname>Davis</surname><given-names>D</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Schlossmacher</surname><given-names>M</given-names></name><name><surname>Whaley</surname><given-names>J</given-names></name><name><surname>Swindlehurst</surname><given-names>C</given-names></name><name><surname>McCormack</surname><given-names>R</given-names></name><name><surname>Wolfert</surname><given-names>R</given-names></name><name><surname>Selkoe</surname><given-names>D</given-names></name><name><surname>Lieberburg</surname><given-names>I</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name></person-group><article-title>Isolation and quantification of soluble Alzheimer’s
beta-peptide from biological fluids</article-title><source>Nature</source><year>1992</year><volume>359</volume><fpage>325</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1038/359325a0</pub-id><pub-id pub-id-type="pmid">1406936</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atwal</surname><given-names>JK</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chiu</surname><given-names>C</given-names></name><name><surname>Mortensen</surname><given-names>DL</given-names></name><name><surname>Meilandt</surname><given-names>WJ</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Heise</surname><given-names>CE</given-names></name><name><surname>Hoyte</surname><given-names>K</given-names></name><name><surname>Luk</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Rouge</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lazarus</surname><given-names>RA</given-names></name><name><surname>Scearce-Levie</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Tessier-Lavigne</surname><given-names>M</given-names></name><name><surname>Watts</surname><given-names>RJ</given-names></name></person-group><article-title>A therapeutic antibody targeting BACE1 inhibits
amyloid-beta production in vivo</article-title><source>Sci Transl Med</source><year>2011</year><volume>3</volume><fpage>84ra43</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3002254</pub-id><pub-id pub-id-type="pmid">21613622</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Araki</surname><given-names>W</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Tabira</surname><given-names>T</given-names></name></person-group><article-title>Amino-truncated amyloid beta-peptide (Abeta5-40/42)
produced from caspase-cleaved amyloid precursor protein is deposited in
Alzheimer’s disease brain</article-title><source>FASEB J</source><year>2004</year><volume>18</volume><fpage>1755</fpage><lpage>1757</lpage><pub-id pub-id-type="pmid">15364896</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miners</surname><given-names>JS</given-names></name><name><surname>Barua</surname><given-names>N</given-names></name><name><surname>Kehoe</surname><given-names>PG</given-names></name><name><surname>Gill</surname><given-names>S</given-names></name><name><surname>Love</surname><given-names>S</given-names></name></person-group><article-title>Abeta-degrading enzymes: potential for treatment of
Alzheimer disease</article-title><source>J Neuropathol Exp Neurol</source><year>2011</year><volume>70</volume><fpage>944</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e3182345e46</pub-id><pub-id pub-id-type="pmid">22002425</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fluhrer</surname><given-names>R</given-names></name><name><surname>Multhaup</surname><given-names>G</given-names></name><name><surname>Schlicksupp</surname><given-names>A</given-names></name><name><surname>Okochi</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Lammich</surname><given-names>S</given-names></name><name><surname>Willem</surname><given-names>M</given-names></name><name><surname>Westmeyer</surname><given-names>G</given-names></name><name><surname>Bode</surname><given-names>W</given-names></name><name><surname>Walter</surname><given-names>J</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name></person-group><article-title>Identification of a beta-secretase activity, which
truncates amyloid beta-peptide after its presenilin-dependent
generation</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>5531</fpage><lpage>5538</lpage><pub-id pub-id-type="doi">10.1074/jbc.M211485200</pub-id><pub-id pub-id-type="pmid"></pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>XP</given-names></name><name><surname>Tugusheva</surname><given-names>K</given-names></name><name><surname>Bruce</surname><given-names>JE</given-names></name><name><surname>Lucka</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>GX</given-names></name><name><surname>Chen-Dodson</surname><given-names>E</given-names></name><name><surname>Price</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Sardana</surname><given-names>MK</given-names></name><name><surname>Hazuda</surname><given-names>DJ</given-names></name></person-group><article-title>Beta-secretase cleavage at amino acid residue 34 in
the amyloid beta peptide is dependent upon gamma-secretase
activity</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>21286</fpage><lpage>21294</lpage><pub-id pub-id-type="doi">10.1074/jbc.M209859200</pub-id><pub-id pub-id-type="pmid">12665519</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Bogdanovic</surname><given-names>N</given-names></name><name><surname>Gustavsson</surname><given-names>MK</given-names></name><name><surname>Volkmann</surname><given-names>I</given-names></name><name><surname>Brinkmalm</surname><given-names>G</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name></person-group><article-title>Mass spectrometric characterization of brain amyloid
beta isoform signatures in familial and sporadic Alzheimer’s
disease</article-title><source>Acta Neuropathol</source><year>2010</year><volume>120</volume><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1007/s00401-010-0690-1</pub-id><pub-id pub-id-type="pmid">20419305</pub-id></element-citation></ref></ref-list></back></article>